 Platelet antiaggregate activity Calcium ions act second messenger agonists increases intracellular calcium changes shape aggregation release reactions Changes platelet function migraine sufferers evidence hyperaggregability migraine attack platelet aggregation platelet-rich plasma PRP nicardipine-treated migraine sufferers dihydropyridine derivatives adenosine diphosphate ADP epinephrine-induced aggregation Aggregation mumol/L arachidonic acid similar PRP control subjects untreated migraine sufferers mumol/L ADP-induced aggregation PRP migraine sufferers Treatment mg nicardipine times months mumol/L ADP-induced aggregation nicardipine migraine pathogenic mechanisms platelets